Chief Executive Officer
Dan has experience and success in founding and building biopharmaceutical companies. He holds a Ph.D. in Medical Sciences from the University of New Mexico School of Medicine and was a postdoctoral scholar at Duke University Medical Center. He founded Microgenics Corporation. At Microgenics, Dan invented the CEDIA™ immunoassay system used in clinical laboratories throughout the world. CEDIA™ immunoassays now sell over $1B annually: please see www.usdiagnostics.roche.com and then search for CEDIA™ on their website; repeat at www.thermofisher.com. For this work, the American Association for Clinical Chemistry (AACC) awarded the 2015 biennial Ullman Prize for Technology Innovation to Dr. Henderson.
Dan also founded Calydon where he genetically engineered adenovirus targeting prostate cancer. For this work he was recognized as one of the two pioneers in the field of oncolytic virotherapy (Scientific American, “Tumor Busting Viruses”, October 2003). Calydon was sold to Cell Genesys. 2015 saw the first FDA approved oncolytic virus, a herpesvirus for melanoma.
Dr. Henderson also co-founded PaxVax, a manufacturer and developer of vaccines for travelers to countries without adequate water sanitation (Typhoid, Cholera and Hepatitis A) and the U.S. Military (Anthrax) (see www.paxvax.com). PaxVax was named Best Early-Stage Vaccine Biotech company at the 16th annual World Vaccine Congress in Washington, D.C., March, 2016 and received FDA approval for a Single Dose Oral Cholera vaccine in June. Dan holds 34 issued US Patents.
Member of the Board of Directors
Durga has over 25 years of global commercial biopharma experience. After an initial spell as a sales representative at Parke-Davis, he took on roles of increasing responsibility at major global pharmaceutical companies including Merck, Genentech and Amgen in the areas of Marketing, Product Development, Alliance Management and Business Development.
Durga started his 15-year career at Merck & Co, Inc. in pricing and then held U.S. and global roles that included U.S. brand management, business development and emerging markets. He ultimately joined the Vaccine Division as Sr. Director of International Commercial Operations and later Executive Director for the Eastern Europe Middle East and Africa region. Durga supported four ex-US launches and helped Merck Vaccines quadruple annual sales to $4 billion to become the world’s number one vaccine company. Durga is currently the Chief Business Officer of SutroVax.
Durga holds an MBA from Georgetown University where he received the Dean’s Citation for distinguished service and leadership.
Non-Executive Chairman of the Board
Jan graduated from West Point in 1966, received a Ph.D. in nuclear engineering from the University of Virginia, and completed a one-year fellowship at the Kennedy School of Government, Harvard University. His expertise includes project management, chemical and biological defense technology, and nuclear and missile defense systems. Jan’s Army career included leadership assignments focused on the acquisition of major defense systems, chemical-biological defense technology, missile defense technology, nuclear weapons, and developmental testing. He led two major research, development, and engineering centers, two national test ranges, and a chemical munitions storage facility.
After thirty years with the United States Army, he retired in 1996 as a Major General, and subsequently became a senior vice president and partner at the Bechtel Corporation. Jan then spent 13 years with Bechtel where he was president of Bechtel’s 5,000-person Defense and Space business (2003-2006). Jan was Deputy Laboratory Director of the Los Alamos National Laboratory, from 2006-2009. In this capacity, he was responsible for oversight and integration of the daily operations of the laboratory with focus on safety, security, business services, environmental management, and infrastructure. Jan has served as a board member of a number of companies, including Bechtel National, Inc., Kwajalein Range Services (Chair), Bechtel Bettis, Inc., Universities Space Research Association (Chair), and the Armed Services YMCA.
John graduated with High Honors from Princeton in 1968 and received a Harvard MBA in 1970. He was Co-Head of Hamblet and Hayes from 1971 to 1980, when H&H was sold to CIBA-Geigy. During the next seventeen years John was with CIBA-Geigy (now renamed to Novartis), rising to become a Senior Vice President. During that period, he held many different positions including head of various points of Finance, Strategy, Business Development, Licensing, Policy, State and Federal Government Affairs, Pharmacoeconomics Research, QC/QA, Safety, Health, and Environment, and Regulatory Compliance. He also oversaw the over the counter business, CIBA-Corning Diagnostics, Biocine (a joint venture with Chiron in the Vaccine business), and the US Generics business.
After retiring from CIBA-Geigy, John was CEO of Covance Biotechnology Services, Inc., Research Triangle Park, NC, a contract manufacturer of Biopharma active ingredients (later sold to AKZO NOBEL), CEO of Integrated Biosystems, Inc., Napa, CA, a manufacturer of production equipment for Bio Pharmaceutical customers (e.g., Genentech, Amgen); (later sold to Stedim, SA, France); and President of Bausch & Lomb, London, where he oversaw Europe, Middle East & Africa. John had charge of the entire portfolio of eye care products (Surgical, Pharma, and Vision Care), representing around $2.5B in sales.
Vice President of Clinical Affairs
Marc was Chief Medical Officer at Paxvax from 2007 to 2015, and Senior Vice President, Medical Affairs and Chief Medical Officer at Vaxgen from 2001-2007. In these two positions Marc ran clinical trials for vaccines aimed at influenza, anthrax and HIV. Marc has held similar positions at Genelabs, Sequus, Boeheringer-Mannheim and Wyeth Ayerst. Marc received his BA. magna cum laude from Yale, his M.D. cum laude from Harvard and his J.D. from Temple. Marc has authored over 100 scientific journal articles.